{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:38:30Z","timestamp":1775666310690,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cases of central diabetes insipidus (CDI) have been reported after COVID-19 infection, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>Woman 37 years old, with rheumatoid arthritis under adalimumab (40 mg twice a month) since December 2018. She was in her usual state of health when she has received the second dose of BNT162b2 mRNA COVID-19 vaccine (June 2021). Seven days later, she started reporting intense thirst and polyuria and consulted her family physician.<\/jats:p><\/jats:sec><jats:sec><jats:title>Blood Analysis<\/jats:title><jats:p>creatinine 0.7 mg\/dL, glucose 95mg\/dL, Na+ 141mEq\/L, K+ 3.9 mEq\/L, TSH 3.8 mcUI\/L (0.38-5.33), FT4 0.9 ng\/dL (0.6-1.1), cortisol 215.4 nmol\/L (185-624), ACTH 21.9 pg\/mL (6- 48), FSH 4.76 UI\/L, LH5.62 UI\/L, estradiol 323 pmol\/L, IGF1 74.8 ng\/mL (88-209), PRL 24.7mcg\/L (3.3-26.7) osmolality 298.2 mOs\/Kg (250- 325); Urine analysis: volume 10200 mL\/24h, osmolality 75 mOs\/Kg (300-900), density 1.002. On water restriction test: 0\u2019 \u2013 Serum osmolality 308.8mOsm\/Kg vs. urine osmolality 61.0 mOsm\/Kg; 60\u2019 - urine osmolality 102 mOsm\/Kg; urine osmolality 1 h after desmopressine was 511mOsm\/kg. MRI revealed no abnormal signs consistent with hypophysitis except for the loss of the posterior pituitary bright spot on T1 weighted imaging. Diagnosis of CDI was assumed, and started therapy with desmopressine. A report of potential adverse effect was addressed to national health authorities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In hypophysitis MRI often shows loss of posterior pituitary bright spot on T1 weighted imaging, pituitary enlargement or stalk thickening but those findings were not present in this patient. To the best of our knowledge, CDI has never been reported following administration of a COVID-19 vaccine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.889074","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T04:45:20Z","timestamp":1651639520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine: A Case Report"],"prefix":"10.3389","volume":"13","author":[{"given":"Bruno","family":"Bou\u00e7a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Rold\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Bogalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Silva-Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01276-8","article-title":"COVID-19 and the Endocrine System: Exploring the Unexplored","volume":"43","author":"Pal","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/v13020270","article-title":"Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype","volume":"13","author":"Pascolo","year":"2021","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186582","article-title":"mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22661","article-title":"mRNA: From a Chemical Blueprint for Protein Production to an Off-the-Shelf Therapeutic","volume":"9","author":"Van Lint","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B5","unstructured":"CDC COVID Data Tracker"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-019-01120-x","article-title":"Imaging Findings in Hypophysitis: A Review","volume":"125","author":"Caranci","year":"2020","journal-title":"Radiol Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","article-title":"Diabetes Insipidus","volume":"5","author":"Christ-Crain","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B8","article-title":"Diagnostic Testing for Diabetes Insipidus","volume-title":"Endotext","author":"Gubbi","year":"2000"},{"key":"B9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune Hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211043386","article-title":"A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine","volume":"9","author":"Murvelashvili","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01627-z","article-title":"Central Diabetes Insipidus (Infundibuloneuro Hypophysitis): A Late Complication of COVID-19 Infection","volume":"44","author":"Misgar","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.172","article-title":"Diabetes Insipidus as a Symptom of Covid-19 Infection: Case Report","volume":"158","author":"Rajevac","year":"2020","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2324709621999954","article-title":"Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection","volume":"9","author":"Sheikh","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104751","article-title":"Delayed Large Local Reactions to mRNA Vaccines","volume":"384","author":"Baeck","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104751","article-title":"Delayed Large Local Reactions to mRNA Vaccines. Reply","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.889074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T04:45:22Z","timestamp":1651639522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.889074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":15,"alternative-id":["10.3389\/fendo.2022.889074"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.889074","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"article-number":"889074"}}